Current Research Studies
A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Standard Of Care Inhaled Antipseudomonal Therapy In People With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa
Clarametyx Phase1B/2A in Cystic Fibrosis
What is the goal of the study?
A phase 1B/2A clinical trial of a monoclonal antibody targeted to Pseudomonas aeruginosa, a common pathogen in lung infections in people with cystic fibrosis. The clinical trial will be conducted in participants who are 18 years of age and older. The investigational product will be administered intravenously with blood collected for pharmacokinetic assays and safety assessments. Standard of care treatment will be maintained. Adverse events will be monitored through the clinical trial.
Who can participate in the study?
Please contact the study team listed below to learn more.